2-[(2-oxopropyl)thio] imidazolium derivates

1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium trifluorosulfonic acid salt

10 mg 520 € available

Art. No. D004
Synonym "L-683.685"; 1,3-Dimethyl-2-(2-oxopropylthio)-4,5-diphenyl-1H-imidazol-3-ium trifluoromethanesulfonate
Molecular Formula C21H21F3N2O4S2 (free cation: C20H21N2OS+)
Molecular Weight 486.53 (free cation: 337.46)
Purity > 95% (NMR)
Appearance off white solid
Solubility Pre-dissolve e.g. 2.02 mg in 207.6 μl DMSO to obtain a 20 mM stock solution - dilute 20 μl of that stock solution with 980 μl buffer (e.g. 50 mM TRIS-HCl, pH 7.5) to obtain a 400 μM solution
Application Inhibitior for transglutaminase.
The molecule was developed to block coagulation factor XIIIa, however the compound inhibits tissue transglutaminase as well. Both enzymes are inhibited with an IC50 of about 0.35 μM.
Storage Store at -20°C
Reference(s) Lorand et al., Exp. Eye Res., 1998, 66:531-6
Barsigian et al., J. Biol. Chem., 1991, 266:22501-9
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • Canceled and rescheduled: Gordon Research Conference

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Canceled and rescheduled: Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy